Market News AIOpen the app

Quoin Pharmaceuticals shares news about a study showing good results for its treatment QRX003 in kids.

TrialRead the original at SEC EDGAR
Good for QNRX

One child’s skin and itch improved through 21 months, and 4 of 6 study participants improved after 12 weeks. These early results support Quoin’s drug, but a larger study is still underway.

QNRX · Quoin Pharmaceuticals Ltd.

AI read · Good for QNRX

The AI's read

The results add one child’s experience to early study findings. The report says no treatment-related side effects were reported, which adds to the positive signs. Still, one case and a 6-person interim group cannot show how most patients will respond. Quoin expects results from its larger study in the second quarter of 2027.

Get alerts for QNRX

Follow Quoin Pharmaceuticals Ltd. (QNRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for QNRX
Free on the App Store and Google Play, or on the web.